Head to Head Analysis: Cyclo Therapeutics (NASDAQ:CYTH) and SOPHiA GENETICS (NASDAQ:SOPH)

Cyclo Therapeutics (NASDAQ:CYTH) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Profitability

This table compares Cyclo Therapeutics and SOPHiA GENETICS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclo Therapeutics	-1,830.27%	-2,741.89%	-269.95%
SOPHiA GENETICS	-102.84%	-47.40%	-34.54%

Institutional & Insider Ownership

68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by company insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Cyclo Therapeutics and SOPHiA GENETICS”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclo Therapeutics	$1.13 million	18.19	-$20.06 million	($1.00)	-0.72
SOPHiA GENETICS	$64.94 million	3.76	-$78.98 million	($1.12)	-3.33

Cyclo Therapeutics has higher earnings, but lower revenue than SOPHiA GENETICS. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Cyclo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cyclo Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Cyclo Therapeutics and SOPHiA GENETICS, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclo Therapeutics	0	2	1	0	2.33
SOPHiA GENETICS	0	1	3	0	2.75

Cyclo Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 31.94%. SOPHiA GENETICS has a consensus target price of $6.50, indicating a potential upside of 74.26%. Given SOPHiA GENETICS’s stronger consensus rating and higher possible upside, analysts plainly believe SOPHiA GENETICS is more favorable than Cyclo Therapeutics.

Summary

SOPHiA GENETICS beats Cyclo Therapeutics on 8 of the 14 factors compared between the two stocks.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.